A trial of decitabine and ECF chemotherapy for advanced cancer of the food pipe (oesophageal cancer)
Cancer type:
Status:
Phase:
This trial was looking at a drug called decitabine in combination with ECF chemotherapy for advanced cancer of the food pipe (oesophageal cancer).
Doctors often treat oesophageal cancer with chemotherapy and surgery. One of the most common types of chemotherapy for oesophageal cancer is a combination of drugs called ECF. This is the chemotherapy drugs epirubicin, cisplatin and fluorouracil (5FU).
In this trial, doctors wanted to see if another drug called decitabine, made ECF work better. Decitabine works by changing the activity of some of the 
in the cancer cells. This may make the cells more sensitive to ECF. Doctors hoped that adding this new drug would make ECF more effective.
The aims of the trial were to find out
- The best dose of decitabine to give
- What the side effects were
- How well decitabine and ECF worked together
Summary of results
Despite attempting to contact the trial team, we have been unable to get any results for this trial.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Prof Mark Middleton
Supported by
Experimental Cancer Medicine Centre (ECMC)
MGI Pharma Inc
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
